{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05576077",
            "orgStudyIdInfo": {
                "id": "TBio-4101-001"
            },
            "organization": {
                "fullName": "Turnstone Biologics, Corp.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors",
            "officialTitle": "A Phase 1b Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (STARLING)",
            "acronym": "STARLING",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-tbio-til-and-pembrolizumab-in-patients-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-01-17",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-06-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-10-07",
            "studyFirstSubmitQcDate": "2022-10-07",
            "studyFirstPostDateStruct": {
                "date": "2022-10-12",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-30",
                "type": "ESTIMATED"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Turnstone Biologics, Corp.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.",
            "detailedDescription": "This is a Phase 1 study to investigate TBio-4101. TBio-4101 is an autologous tumor infiltrating lymphocyte (TIL) therapy that utilizes tumor specific antigens to select, sort, and expand patient-specific tumor-reactive T-cells to be reinfused into the patient. The adoptive cell therapy is further enhanced through the use of non-myeloablative chemotherapy prior to TIL infusion, followed by the TIL plus IL-2 infusion. Low-dose radiation therapy is administered prior to and after TIL plus IL-2 infusion. Pembrolizumab is provided after the resolution of IL-2 toxicities. The trial is open to solid tumors of varying tumor mutational burdens."
        },
        "conditionsModule": {
            "conditions": [
                "Breast Cancer",
                "Colorectal Cancer",
                "Uveal Melanoma",
                "Cutaneous Melanoma",
                "Non-Small Cell Lung Cancer",
                "Head and Neck Squamous Cell Carcinoma"
            ],
            "keywords": [
                "MSS-CRC",
                "TIL",
                "Tumor infiltrating lymphocyte",
                "TNBC",
                "HR+ Breast",
                "ER+ Breast",
                "MSI-CRC",
                "personalized medicine",
                "ocular melanoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Patients enrolled into a Cohort based on malignancy.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Breast Cancer",
                    "type": "EXPERIMENTAL",
                    "description": "Patients with locally advanced or metastatic breast cancer that has failed or is intolerant to standard of care therapies. Includes, HER2+, HER 2-, TNBC.",
                    "interventionNames": [
                        "Biological: TBio-4101",
                        "Drug: Pembrolizumab"
                    ]
                },
                {
                    "label": "Colorectal carcinoma",
                    "type": "EXPERIMENTAL",
                    "description": "Patients with advanced, metastatic colorectal adenocarcinoma who have failed or are intolerant to at least one line of therapy that included either irinotecan or oxaliplatin.",
                    "interventionNames": [
                        "Biological: TBio-4101",
                        "Drug: Pembrolizumab"
                    ]
                },
                {
                    "label": "Uveal Melanoma",
                    "type": "EXPERIMENTAL",
                    "description": "Patients with advanced, metastatic uveal melanoma.",
                    "interventionNames": [
                        "Biological: TBio-4101",
                        "Drug: Pembrolizumab"
                    ]
                },
                {
                    "label": "Cutaneous Melanoma",
                    "type": "EXPERIMENTAL",
                    "description": "Patients with cutaneous melanoma who have experienced disease progression following a PD-1 or PD-L1 inhibitor.",
                    "interventionNames": [
                        "Biological: TBio-4101",
                        "Drug: Pembrolizumab"
                    ]
                },
                {
                    "label": "Non-Small Cell Lung Cancer",
                    "type": "EXPERIMENTAL",
                    "description": "Patients with non-small cell lung cancer who have experienced disease progression following platinum containing chemotherapy and/or PD-1 or PD-L1 inhibitor.",
                    "interventionNames": [
                        "Biological: TBio-4101",
                        "Drug: Pembrolizumab"
                    ]
                },
                {
                    "label": "Head and Neck Squamous Cell Carcinoma",
                    "type": "EXPERIMENTAL",
                    "description": "* Patients with head and neck squamous cell carcinoma who have received no prior therapy for metastatic disease\n* Patients with head and neck squamous cell carcinoma who are PD-1/PD-L1 inhibitor na\u00efve at the time of TIL harvest and will be treated with TBio-4101 at the time of progression, inadequate response or intolerance to the PD-1/PD-L1 inhibitor-based standard of care regimen given on study.",
                    "interventionNames": [
                        "Biological: TBio-4101",
                        "Drug: Pembrolizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "TBio-4101",
                    "description": "TBio-4101 is an autologous selected and expanded tumor infiltrating lymphocyte (TIL) product generated following ex vivo expansion of tumor reactive TIL population found in tumor harvest. After preparation with non-myeloablative lymphodepletion chemotherapy (cyclophosphamide and fludarabine) followed by low dose radiation,TBio-4101, and IL-2.",
                    "armGroupLabels": [
                        "Breast Cancer",
                        "Colorectal carcinoma",
                        "Cutaneous Melanoma",
                        "Head and Neck Squamous Cell Carcinoma",
                        "Non-Small Cell Lung Cancer",
                        "Uveal Melanoma"
                    ],
                    "otherNames": [
                        "TIL, autologous, tumor-reactive, T-cell product"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pembrolizumab",
                    "description": "Pembrolizumab will be administered after TIL infusion and continue every 3-6 weeks for up to 2 years.",
                    "armGroupLabels": [
                        "Breast Cancer",
                        "Colorectal carcinoma",
                        "Cutaneous Melanoma",
                        "Head and Neck Squamous Cell Carcinoma",
                        "Non-Small Cell Lung Cancer",
                        "Uveal Melanoma"
                    ],
                    "otherNames": [
                        "Keytruda"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety and tolerability",
                    "description": "The incidence of treatment-emergent adverse events will be tabulated using NCI CTCAE v5.0",
                    "timeFrame": "25 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Proportion of patients with a response (ORR)",
                    "description": "Percentage of all patients and within each cancer indication with a CR or PR as assessed by the independent central radiologist using RECIST 1.1 and iRECIST",
                    "timeFrame": "25 months"
                },
                {
                    "measure": "Estimated Disease Control Rate (DCR)",
                    "description": "Portion of patient whose best response is a CR, PR, or stable disease (SD) as assessed by the independent central radiologist using RECIST v1.1 and iRECIST",
                    "timeFrame": "25 months"
                },
                {
                    "measure": "Estimated Duration of Response (DoR)",
                    "description": "Duration of response, as measured in weeks, that patients with a CR or PR have no progressed (PD), as assessed by the independent central radiologist using RECIST v1.1 and iRECIST,",
                    "timeFrame": "25 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Advanced or metastatic breast carcinoma, colorectal adenocarcinoma, uveal melanoma, cutaneous melanoma, non-small cell lung cancer, or head and neck squamous cell carcinoma that has failed or is refractory to standard of care therapy\n* Have at least one target lesion that can be used for response assessments and have at least 1 tumor amenable for tissue harvest for TIL manufacturing.\n* ECOG performance status of 0 or 1\n* Demonstrate adequate organ function\n* Additional inclusion criteria exist\n\nKey Exclusion Criteria:\n\n* Known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy or any other form of immunosuppressive\n* Currently infected with HIV Type 1 and Type 2, hepatitis B virus (HBV), hepatitis C virus (HCV), treponema pallidum (e.g., syphilis), West Nile virus (WNV), Human T-lymphotropic virus types 1 or II (HTLV I/II), or cytomegalovirus (CMV)\n* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are radiologically stable\n* Serious cardiac condition, such as uncontrolled hypertension, concurrent congestive heart failure, prior history of Class III/IV cardiac disease (New York Heart Association \\[NYHA\\]), history of cardiac ischemia within the past 6 months, or prior history of cardiac arrhythmia requiring treatment. Patients who are \\> 60 years of age must undergo cardiology clearance exam and cardiac stress test.\n* Prior cell therapy or organ transplant\n* History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, IL-2, or pembrolizumab, or any of their constituents\n* LVEF \u2264 45%\n* FEV1 \u2264 60% of predicted value and DLCO (corrected) \\< 60% of predicted value\n* Chronic anti-coagulant therapy that cannot either be discontinued or temporarily changed\n* Additional exclusion criteria exist",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Thelma Bueno",
                    "role": "CONTACT",
                    "phone": "(843) 321-8490",
                    "email": "STARLINGTumorStudy@kapadi.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Ines Verdon, MD",
                    "affiliation": "Turnstone Biologics, Corp.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of California Irvine",
                    "status": "RECRUITING",
                    "city": "Irvine",
                    "state": "California",
                    "zip": "92868",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Juan Miranda",
                            "role": "CONTACT",
                            "phone": "714-509-2951",
                            "email": "jlmirand@hs.uci.edu"
                        },
                        {
                            "name": "Ritesh Parajuli",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.66946,
                        "lon": -117.82311
                    }
                },
                {
                    "facility": "University of Miami",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lauren Miro",
                            "role": "CONTACT",
                            "phone": "305-243-7590",
                            "email": "lem183@med.miami.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Orlando Health",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32806",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Adult Oncology Patient Referral",
                            "role": "CONTACT",
                            "email": "r-adultonctrialreferral@orlandohealth.com"
                        },
                        {
                            "name": "Sajeve Thomas, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "Moffitt Cancer Center",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612-9497",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Yvonne Nguyen",
                            "role": "CONTACT",
                            "phone": "813-745-6869",
                            "email": "yvonne.nguyen@moffitt.org"
                        },
                        {
                            "name": "Dae Won Kim",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "Norton Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Louisville",
                    "state": "Kentucky",
                    "zip": "40202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "NCI Research",
                            "role": "CONTACT",
                            "phone": "502-629-2500",
                            "phoneExt": "19460",
                            "email": "earlyphase-nciresearch@nortonhealthcare.org"
                        },
                        {
                            "role": "CONTACT",
                            "phone": "502-629-2500"
                        },
                        {
                            "name": "Jaspreet Grewal, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.25424,
                        "lon": -85.75941
                    }
                },
                {
                    "facility": "Providence Healthcare Research Institute",
                    "status": "RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97213",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Isa Ngirailemesang",
                            "role": "CONTACT",
                            "phone": "503-215-2714",
                            "email": "Isa.Ngirailemesang@providence.org"
                        },
                        {
                            "name": "Patrick Rethwisch",
                            "role": "CONTACT",
                            "email": "Patrick.rethwisch@providence.org"
                        },
                        {
                            "name": "Matthew Taylor",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Allegheny Research Institute",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15224",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lindsey Brown",
                            "role": "CONTACT",
                            "phone": "412-578-5426",
                            "email": "Lindsey.brown@ahn.org"
                        },
                        {
                            "name": "Frankie Houser",
                            "role": "CONTACT",
                            "phone": "(412) 578-1646",
                            "email": "Frankie.Houser2@ahn.org"
                        },
                        {
                            "name": "Yazan Samhouri, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Amber Sherrard",
                            "role": "CONTACT",
                            "phone": "713-563-9710",
                            "email": "AESherrard@mdanderson.org"
                        },
                        {
                            "name": "Ashabari Sprenger",
                            "role": "CONTACT",
                            "email": "amukherjee1@mdanderson.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Medical College of Wisconsin",
                    "status": "RECRUITING",
                    "city": "Milwaukee",
                    "state": "Wisconsin",
                    "zip": "53226",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Abigail Bartosic",
                            "role": "CONTACT",
                            "phone": "414-805-6837",
                            "email": "abartosic@mcw.edu"
                        },
                        {
                            "role": "CONTACT",
                            "phone": "(414) 805-5136"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.0389,
                        "lon": -87.90647
                    }
                },
                {
                    "facility": "Princess Margaret Cancer Centre",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 2C1",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Shivali Suri",
                            "role": "CONTACT",
                            "phone": "416-946-4501",
                            "phoneExt": "2639",
                            "email": "Shivali.Suri@uhn.ca"
                        },
                        {
                            "name": "Jeshani Sivakumar",
                            "role": "CONTACT",
                            "email": "jeshani.sivakumar@uhn.ca"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Montreal University Hospital Center",
                    "status": "RECRUITING",
                    "city": "Montr\u00e9al",
                    "state": "Quebec",
                    "zip": "H2X 0C1",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Olivier Landry",
                            "role": "CONTACT",
                            "phone": "514 890-8000",
                            "phoneExt": "31524",
                            "email": "olivier.landry.chum@ssss.gouv.qc.ca"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008545",
                    "term": "Melanoma"
                },
                {
                    "id": "D000077195",
                    "term": "Squamous Cell Carcinoma of Head and Neck"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000018358",
                    "term": "Neuroendocrine Tumors"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                },
                {
                    "id": "D000018326",
                    "term": "Nevi and Melanomas"
                },
                {
                    "id": "D000012878",
                    "term": "Skin Neoplasms"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000002294",
                    "term": "Carcinoma, Squamous Cell"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000006258",
                    "term": "Head and Neck Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5550",
                    "name": "Carcinoma, Squamous Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M11528",
                    "name": "Melanoma",
                    "asFound": "Melanoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3212",
                    "name": "Melanoma, Cutaneous Malignant",
                    "relevance": "LOW"
                },
                {
                    "id": "M1689",
                    "name": "Squamous Cell Carcinoma of Head and Neck",
                    "asFound": "Head and Neck Squamous Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20495",
                    "name": "Neuroendocrine Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M12448",
                    "name": "Nevus, Pigmented",
                    "relevance": "LOW"
                },
                {
                    "id": "M12446",
                    "name": "Nevus",
                    "relevance": "LOW"
                },
                {
                    "id": "M20470",
                    "name": "Nevi and Melanomas",
                    "relevance": "LOW"
                },
                {
                    "id": "M15681",
                    "name": "Skin Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "T3099",
                    "name": "Intraocular Melanoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T4192",
                    "name": "Ocular Melanoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T4091",
                    "name": "Neuroendocrine Tumor",
                    "relevance": "LOW"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "relevance": "LOW"
                },
                {
                    "id": "M1671",
                    "name": "Irinotecan",
                    "relevance": "LOW"
                },
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1674",
                    "name": "Oxaliplatin",
                    "relevance": "LOW"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "relevance": "LOW"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}